nach oben

Calcified Tissue International

Erschienen in:

06.09.2018 | Original Research

Irp2 Knockout Causes Osteoporosis by Inhibition of Bone Remodeling

verfasst von: Yaru Zhou, Yu Yang, Yan Liu, Hengrui Chang, Kuanzhi Liu, Xiaojuan Zhang, Yanzhong Chang

Erschienen in: Calcified Tissue International | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

It has been found that iron disorder may lead to osteoporosis. However, the mechanism has been little explored. In the present study, we try to investigate the effects of iron disorder on bone metabolism using Irp2 knockout (Irp2^−/−) mice. Female Irp2^−/− mice were used in this study. Bone mineral density (BMD) was measured by Micro-CT. Serum markers for bone turnover were measured by enzyme-linked immunosorbent assay. Content of iron was measured in bone and liver tissue, and Vitamin D 25-hydroxylase (CYP2R1) content was measured in liver tissue. Relative gene expression involved in iron export and uptake, and some genes involved in activities of osteoblast and osteoclast were all measured by real-time PCR and western blot. Compared to wild-type mice, Irp2^−/− mice exhibited reduced BMD, bone iron deficiency, and hepatic iron overload. Serum levels of 25(OH)D₃ and markers for bone formation such as bone alkaline phosphatase (Balp), bone-gla-protein (BGP), and type I collagen alpha1 chain (Col I α₁) were decreased, while markers for bone resorption including cathepsin K (Ctsk) and tartrate-resistant acid phosphatase (Trap) were all significantly increased. Hepatic CYP2R1 level was decreased in Irp2^−/− mice compared with wild-type control mice. Compared to wild-type C57BL6 control mice, the expression of genes involved in osteoblast activity such as Balp, BGP, and Col I α₁ were all significantly decreased in bone tissue, while genes for osteoclast activity such as Ctsk and Trap were all markedly increased in Irp2^−/− mice at mRNA level. Genes involved in iron storage, uptake, and exporting were also measured in bone tissue. Posttranscriptionally decreased ferritin (FTL), ferroportin 1 (FPN1), and increased transferrin receptor 1 (TfR1) gene expressions have been unexpectedly found in bone tissue of Irp2^−/− mice. Irp2^−/− mice exhibit reduced bone iron content and osteoporosis. Decreased circulating 25(OH)D₃ levels promoted activity of osteoclast, while impaired activity of osteoblast may contribute to pathogenesis of osteoporosis. And, reduced bone iron content may not be totally caused by TfR1-dependent pathways.

Nur mit Berechtigung zugänglich

Rossi F, Perrotta S, Bellini G et al (2014) Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica 99(12):1876–1884CrossRefPubMedPubMedCentral

Guggenbuhl P, Deugnier Y, Boisdet JF et al (2005) Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 16:1809–1814CrossRefPubMed

Valenti L, Varenna M, Fracanzani AL (2009) et, al. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 20:549–555CrossRefPubMed

Sinigaglia L, Fargion S, Fracanzani AL et al (1997) Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol 24(9):1809–1813PubMed

Medeiros DM, Plattner A, Jennings D et al (2002) Bone morphology, strength and density are compromised in iron-deficient rats and exacerbated by calcium restriction. J Nutr 132(10):3135–3141CrossRefPubMed

Medeiros DM, Stoecker B, Plattener A et al (2004) Iron deficiency negatively affects vertebrae and femurs of rats independently of energy intake and body weight. J Nutr 134(11):3061–3067CrossRefPubMed

Li GF, Pan YZ, Sirois P et al (2012) Iron homeostasis in osteoporosis and its clinical implications. Osteoporos Int 23:2403–2408CrossRefPubMed

Yamasaki K, Hagiwara H (2009) Excess iron inhibits osteoblast metabolism. Toxicol Lett 191:211–215CrossRefPubMed

He YF, Ma Y, Gao C et al (2013) Iron overload inhibits osteoblast biological activity through oxidative stress. Biol Trace Elem Res 152(2):292–296CrossRefPubMed

10.

Hentze MW, Muckenthaler MU, Galy B et al (2010) Two to tango:regulation of Mammalian iron metabolism. Cell 9(1):24–38 142(CrossRef

11.

Anderson CP, Shen M, Eisenstein RS et al (2012) Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta 1823(9):1468–1483CrossRefPubMedPubMedCentral

12.

Sanchez M, Galy B, Schwanhaeusser B et al (2011) Iron regulatory protein-1 and -2: transcriptome-wide definition of binding mRNAs and shaping of the cellular proteome by iron regulatory proteins. Blood 118(22):e168–e179CrossRefPubMed

13.

Vashisht AA, Zumbrennen KB, Huang X et al (2009) Control of iron homeostasis by an iron-regulated ubiquitin ligase. Science 326(5953):718–721CrossRefPubMedPubMedCentral

14.

Salahudeen AA, Thompson JW, Ruiz JC et al (2009) An E3 ligase possessing an iron-responsive hemerythrin domain is a regulator of iron homeostasis. Science 326(5953):722–726CrossRefPubMedPubMedCentral

15.

Moroishi T, Nishiyama M, Takeda Y et al (2011) The FBXL5-IRP2 axis is integral to control of iron metabolism in vivo. Cell Metab 14(3):339–351CrossRefPubMed

16.

Ishii KA, Fumoto T, Iwai K et al (2009) Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 15(3):259–266CrossRefPubMed

17.

Yang Q, Jian J, Abramson SB et al (2011) Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J Bone Miner Res 26:1188–1196CrossRefPubMed

18.

Chang YZ, Qian ZM, Wang K et al (2005) Effects of development and iron status on ceruloplasmin expression in rat brain. J Cell Physiol 204(2):623–631CrossRefPubMed

19.

Machado I, Bergmann G, Pistón M (2016) A simple and fast ultrasound-assisted extraction procedure for Fe and Zn determination in milk-based infant formulas using flame atomic absorption spectrometry (FAAS). Food Chem 194:373–376CrossRefPubMed

20.

Shi ZH, Nie G, Duan XL, Rouault T, Wu WS, Ning B, Zhang N, Chang YZ, Zhao BL (2010) Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine-induceddopaminergic cell damage: implication for neuroprotection in Parkinson’s disease. Antioxid Redox Signal 2010;13(6):783–796CrossRefPubMed

21.

Winter WE, Bazydlo LA, Harris NS (2014) The molecular biology of human iron metabolism. Lab Med 45(2):92–102CrossRefPubMed

22.

Li J, Hou Y, Zhang S et al (2013) Excess iron undermined bone load-bearing capacity through tumor necrosis factor-alpha-dependent osteoclastic activation in mice. Biomed Rep 1:85–88CrossRefPubMed

23.

D’Amelio P, Cristofaro MA, Tamone C et al (2008) Role of iron metabolism and oxidative damage in postmenopausal bone loss. Bone 43:1010–1015CrossRefPubMed

24.

Meyron-Holtz EG, Ghosh MC, Rouault TA (2004) Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo. Science 306:2087–2090CrossRefPubMed

25.

Meyron-Holtz EG, Ghosh MC, Iwai K et al (2004) Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO J 23:386–395CrossRefPubMedPubMedCentral

26.

Kim HY, Klausner RD, Rouault TA (1995) Translational repressor activity is equivalent and is quantitatively predicted by in vitro RNA binding for two iron-responsive element binding proteins, IRP1 and IRP2. J Biol Chem 270:4983–4986CrossRefPubMed

27.

Ghosh MC, Zhang DL, Jeong SY et al (2013) Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2α. Cell Metab 17(2):271–281CrossRefPubMedPubMedCentral

28.

Cooperman SS, Meyron-Holtz EG, Olivierre-Wilson H et al (2005) Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2. Blood 106(3):1084–1091CrossRefPubMedPubMedCentral

29.

Zhou J, Ye S, Fujiwara T et al (2013) Steap4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron/reactive oxygen species (ROS) levels and cAMP response element-binding protein (CREB) activation. J Biol Chem 288(42):30064–30074CrossRefPubMedPubMedCentral

30.

Guggenbuhl P, Fergelot P, Doyard M et al (2011) Bone status in a mouse model of genetic hemochromatosis. Osteoporos Int 22(8):2313–2319CrossRefPubMed

31.

Doyard M, Chappard D, Leroyer P et al (2016) Decreased bone formation explains osteoporosis in a genetic mouse model of hemochromatosiss. PLoS ONE 11(2):e0148292CrossRefPubMedPubMedCentral

32.

Mediero A, Cronstein BN (2013) Adenosine and bone metabolism. Trends Endocrinol Metab 24(6):290–300CrossRefPubMedPubMedCentral

33.

Uemura H, Yasui T, Kiyokawa M et al (2002) Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. J Endocrinol 174(2):353–359CrossRefPubMed

34.

Price PA, Parthemore JG, Deftos LJ (1980) New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bonedisease. J Clin Invest 66(5):878–883CrossRefPubMedPubMedCentral

35.

Zoch ML, Clemens TL, Riddle RC (2016) New insights into the biology of osteocalcin. Bone 82:42–49CrossRefPubMed

36.

Song YE, Tan H, Liu KJ et al (2011) Effect of fluoride exposure on bone metabolism indicators ALP, BALP, and BGP. Environ Health Prev Med 16(3):158–163CrossRefPubMed

37.

Kemper O, Herten M, Fischer J et al (2014) Prostacyclin suppresses twist expression in the presence of indomethacin in bone marrow-derived mesenchymal stromal cells. Med Sci Monit 20:2219–2227CrossRefPubMedPubMedCentral

38.

Inui T, Ishibashi O, Inaoka T et al (1997) Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J Biol Chem 272(13):8109–8112CrossRefPubMed

39.

Galy B, Ferring D, Minana B et al (2005) Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2). Blood 106(7):2580–2589CrossRefPubMed

40.

Arosio P, Elia L, Poli M (2017) Ferritin, cellular iron storage and regulation. IUBMB Life 69(6):414–422CrossRefPubMed

41.

Ganz T (2005) Cellular iron: ferroportin is the only way out. Cell Metab 1(3):155–157CrossRefPubMed

42.

Rochette L, Gudjoncik A, Guenancia C et al (2015) The iron-regulatory hormone hepcidin: a possible therapeutic target? Pharmacol Ther 146:35–52CrossRefPubMed

43.

Wang G, Shao A, Hu W et al (2015) Changes of ferrous iron and its transporters after intracerebral hemorrhage in rats. Int J Clin Exp Pathol 8(9):10671–10679PubMedPubMedCentral

44.

Rice AE, Mendez MJ, Hokanson CA et al (2009) Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter. J Mol Biol 386(3):717–732CrossRefPubMedPubMedCentral

45.

Zumbrennen-Bullough KB, Becker L, Garrett L et al (2014) Abnormal brain iron metabolism in Irp2 deficient mice is associated with mild neurological and behavioral impairments. PLoS ONE 9(6):e98072CrossRefPubMedPubMedCentral

Titel: Irp2 Knockout Causes Osteoporosis by Inhibition of Bone Remodeling
verfasst von: Yaru Zhou
Yu Yang
Yan Liu
Hengrui Chang
Kuanzhi Liu
Xiaojuan Zhang
Yanzhong Chang
Publikationsdatum: 06.09.2018
Verlag: Springer US
Erschienen in: Calcified Tissue International / Ausgabe 1/2019
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-018-0469-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Irp2 Knockout Causes Osteoporosis by Inhibition of Bone Remodeling

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

OFELIA: Prevalence of Osteoporosis in Fragility Fracture Patients

Elevated Red Blood Cell Distribution Width Is Associated with Morphometric Vertebral Fracture in Community-Dwelling Older Adults, Independent of Anemia, Inflammation, and Nutritional Status: The Korean Urban Rural Elderly (KURE) Study

Atrophic Gastritis as a Risk Factor for Bone Loss in Premenopausal Women in Their 40s: A Retrospective Cohort Study

A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture

Metacarpal Indices and Their Association with Fracture in South African Children and Adolescents

Metformin Alleviates the Bone Loss Induced by Ketogenic Diet: An In Vivo Study in Mice

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin